Finite nucleos(t)ide analogue therapy in hepatitis B e antigen‐negative chronic hepatitis B: From an “option” to an “active recommendation”

Nucleos(t)ide analogue (Nuc) including entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide may suppress hepatitis B virus (HBV) DNA profoundly but have no direct action on covalently closed circular DNA, which is a very stable template for HBV production. Therefore, decades of long‐term Nuc therapy are required to maintain HBV suppression and to achieve hepatitis B surface antigen (HBsAg) loss in hepatitis B e antigen (HBeAg)‐negative patients. However, there are concerns including financial burden, adherence, and willingness for indefinite long‐term Nuc therapy. Patients lost to follow‐up and hence not monitored may risk severe relapse that may deteriorate to hepatic decompensation or even hepatic failure. Cessation of Nuc therapy in HBeAg‐negative patients was initially considered in early 2000s. Earlier findings in Asian patients that finite Nuc therapy over 2–3 years is feasible and safe have founded Asian‐Pacific Association for the Study of Liver stopping rule since 2008. Subsequent studies have confirmed the feasibility and safety of the strategy of finite Nuc therapy, which has finally been accepted as “an option” by American and European liver associations since 2016. More recent large studies since 2018 have further confirmed the pivotal finding of greatly increased HBsAg loss rate (~5‐year 39%) after stopping Nuc therapy. With the high HBsAg loss rate as the main justification, the paradigm shift from indefinite long‐term therapy to finite Nuc therapy in HBeAg‐negative patients has been changing from an “option” to an “active recommendation” aiming to achieve HBsAg loss. More studies are needed to fine‐tuning the strategy, including research for the optimal duration of consolidation therapy, timing to stop, and to start retreatment.